# DESCRIPTION

## FIELD OF THE INVENTION

## BACKGROUND OF THE INVENTION

## SUMMARY OF THE INVENTION

## DEFINITIONS

### Chemical Definitions

### Other Definitions

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

### Compounds

### Further Embodiments of Formula I

### Pharmaceutical Compositions, Kits, and Administration

### Methods of Treatment

### Diagnostic Methods

## EXAMPLES

### Preparation of Synthetic Intermediates

### N-(6-02-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide (1; QC-01-178))

### (2S,4R)-1-[(2S)-3,3-Dimethyl-2-(3-{2-[2-(3-{5H-pyrido[4,3-b]indol-7-yl}propanamido)ethoxy]ethoxy}propanamido)butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-earboxamide (8; FMF-05-129-1)

### 2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}-N-{2-[2-(2-{2-[(5-{5H-pyrido[4,3-b]indol-7-yl}pyridin-2-yl)oxy]acetamido}ethoxy)ethoxy]ethyl}acetamide (15; FMF-05-183-1)

### N-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethyl]-2-[(5-{5H-pyrido [4,3-b]indol-7-yl}pyridirt-2-yl)oxy]acetamide (19; FMF-05-167-1)

### Tau Degradation Assays

### In Vivo Assay

## Equivalents And Scope

